Transitioning from Early Stage to Registrational/Pivotal Stage Development

Arvin is the Chief Medical Officer at Pheon. He was previously the CMO at Mersana in addition to spending over a decade at Bristol Myers Squibb in a variety of leadership roles focused on early and late-stage clinical development of oncology, hematology, and immuno-oncology therapies. Arvin received a B.A. from Rutgers College and M.D. and Ph.D. degrees from Rutgers Robert Wood Johnson Medical School and completed training in internal medicine at Beth Israel Deaconess, Harvard Medical School and in oncology at Memorial Sloan-Kettering Cancer Center.

Lise Kjems, M.D., Ph.D., brings a remarkable 20+ year career in R&D spanning a broad range of therapeutic categories, including liver disease, endocrinology, rare disease, autoimmune, gastrointestinal and infectious diseases. She has a proven track record in leading high performing teams and delivering on complex programs, with deep experience in development from first-in-human studies through product approval. Holding previous executive leadership positions at notable pharmaceutical and biotechnology companies, Dr. Kjems is highly experienced in delivering novel and effective therapies to patients in need.Prior to joining Ocelot Bio, Dr. Kjems was the Chief Medical Officer at Cyclo Therapeutics where she led its global program evaluating Trappsol® Cyclo™ in Alzheimer’s and rare disease. Before Cyclo Therapeutics, Dr. Kjems was essential in bringing Albireo Pharma’s drug Bylvay® through its Phase 3 program in progressive familial intrahepatic cholestasis (PFIC) to FDA and EMA approvals, as well as launching pivotal Phase 3 trials for Bylvay in biliary atresia and Alagille syndrome. Earlier in her career, she held various positions of increasing responsibility at Aldeyra Therapeutics, Intarcia Therapeutics, Ionis Pharmaceuticals, Johnson & Johnson and Novartis.Dr. Kjems received her M.D. and her Ph.D. in Physiology from the University of Copenhagen Medical Faculty Denmark. She was an invited guest research fellow at the University of Southern California, Keck School of Medicine, and an industrial research fellow at Novo Nordisk A/S Bagsvaerd Denmark & University of Copenhagen.

Dr. Johan Baeck, the Chief. Medical Officer at Promontory Therapeutics, brings over 14 years of expertise in immuno-oncology clinical development. His career has spanned both smaller, emerging biotech firms and large pharmaceutical companies, including a notable nine-year tenure at Novartis. Specializing in treatments for liquid and solid tumors, Dr. Baeck’s extensive experience encompasses his fifth role in biotech, demonstrating his seasoned insight into drug development processes. His dual exposure to both dynamic biotech environments and structured big pharma settings equips him with a comprehensive understanding of oncology patient care and therapeutic innovation.

TBD